3,560 material Form 8-K filings that 2,489 companies we cover made with the SEC in October 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 2,508 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Sizzle Acquisition Corp. II filed an investor presentation from Trasteel Holding S.A. under Item 7.01, furnished as Exhibit 99.1, for the business combination agreed on April 13, 2026. The presentation shows Trasteel's unaudited, preliminary first-half 2026 revenue, gross profit and EBITDA rising sharply from the prior-year period. The figures are management IFRS numbers and are subject to change, and the deal remains pending.
H1 2026 total revenues of $1,192.4 million, up 40.0% from $851.8 million in H1 2025
H1 2026 gross profit of $105.9 million, up 36.9% from $77.4 million
H1 2026 EBITDA of $50.7 million, up 80.8% from $28.0 million, per unaudited IFRS management figures
EQT Corporation said it expects to report a total gain on derivatives of $100 million for the three months ended September 30, 2026, including $70 million in net cash settlements received, with $68 million from NYMEX natural gas hedges. The figures are preliminary and will be finalized in the company's Form 10-Q or earnings release, so they give shareholders an early read on hedging results rather than a full picture of operating performance.
Expected total gain on derivatives of $100 million for the quarter ended September 30, 2026
Net cash settlements received on derivatives of $70 million, including $68 million on NYMEX natural gas hedges and $2 million on basis and liquids hedges
No premiums paid or received for derivatives that settled during the period
Amounts are preliminary and will be reported in the Form 10-Q or corresponding earnings release
AZZ reported second-quarter fiscal 2027 sales of $486.9 million, up 16.7%, and adjusted diluted EPS of $2.00, up 29.0%, for the quarter ended August 31, 2026. GAAP diluted EPS fell 34.2% to $1.94 because the prior-year quarter included a large AVAIL joint venture gain, and the company raised its fiscal 2027 guidance for sales, adjusted EBITDA and adjusted diluted EPS.
Second-quarter sales were $486.9 million; Metal Coatings rose 22.9% to $233.5 million and Precoat Metals rose 11.5% to $253.4 million.
GAAP diluted EPS was $1.94, down 34.2%; adjusted diluted EPS was $2.00, up 29.0%.
Fiscal 2027 adjusted diluted EPS guidance was raised to $7.00-$7.30 from $6.75-$7.15, and sales guidance to $1.825-$1.875 billion from $1.80-$1.85 billion.
During the first half, AZZ repurchased $20.0 million of common stock and completed the $57.5 million Seattle Galvanizing acquisition.
Better Home & Finance Holding Company reported preliminary third-quarter 2026 Loan Volume of $1.39 billion, up 15% from a year earlier and toward the lower end of its prior guidance range of $1.375 billion to $1.525 billion. The company also reported Tinman AI platform volume of $790 million, up 64%, and said it has implemented about $13.2 million in annualized expense reductions, with a further $51 million targeted. The results are preliminary, the company did not report profit or earnings per share in this filing, and the figures remain subject to its closing procedures.
Total Loan Volume of $1.39 billion, up 15% from $1.21 billion in Q3 2025, within guidance of $1.375 billion to $1.525 billion
Tinman AI platform volume of $790 million, up 64% from $483 million, about 57% of total Loan Volume
About $13.2 million in annualized expense reductions implemented; $64.2 million annualized targeted once fully implemented
Results are preliminary estimates subject to completion of closing procedures; the company is in a 2-month public proxy fight
McEwen and two subsidiaries agreed to sell their Fuller and Paymaster properties and a surface rights parcel in Timmins, Ontario, to Dome Mine Ltd., a unit of Discovery Mining Ltd., for total consideration of $55 million. The company also received $13.5 million from assigning a loan receivable from McEwen Copper Inc. to new third-party lenders, which it says adds to its capital for growth spending.
Purchase price is $55 million: $5 million in cash and $50 million in Discovery Mining Ltd. common shares
Discovery shares will be valued using a five-day VWAP on the TSX ending two business days before closing, and are subject to a four-month-and-one-day hold
Closing is expected after customary conditions are met, including TSX approval for the issuance of the Discovery shares
Company says the two transactions provide approximately $68.5 million of additional capital, including the $13.5 million loan assignment
Flyte Aviation furnished a press release reporting preliminary, unaudited third-quarter 2026 revenue of about $2.15 million, up about 110% from $1.02 million in the second quarter. The filing says the auditor has not finished its review, and final results in the Form 10-Q may differ. The filing does not report profit, earnings per share, or guidance.
Preliminary Q3 2026 revenue of about $2.15 million, compared with $1.02 million in Q2 2026
Aviation segment revenue rose 150% sequentially to about $1.87 million; MedTech revenue rose 4% sequentially to about $280,000
Registered platform users exceed 20,000 after more than 13,000 new accounts since the late May 2026 redesign
Results are unaudited and may change once the independent auditor completes its review and the 10-Q is filed
Citigroup reported third-quarter 2026 net income of $5.2 billion, or $2.85 per diluted share, on revenues of $23.8 billion, up from $3.8 billion, or $1.86 per share, a year earlier. The prior-year figures included a $726 million goodwill impairment tied to the Banamex stake sale, so excluding that item, earnings per share rose 27%. Returns to common shareholders totaled $4.1 billion in the quarter, and management said it expects to exceed this year's return target.
Revenues rose 8% to $23.8 billion, driven by Services, Wealth, Markets and Banking, partly offset by All Other.
Reported EPS of $2.85 compared with $1.86 a year earlier; excluding the prior-year notable item, prior-year EPS was $2.24.
Provision for credit losses was $2.6 billion, up 6%, with a net reserve build of $369 million.
Common Equity Tier 1 capital ratio was 12.8%, unchanged from the prior quarter; return on average tangible common equity was 11.5%.
Sizzle II filed a Trasteel press release, furnished under Item 7.01, reporting unaudited first-half 2026 results. Total revenue rose 40.0% to $1,192.4 million, operating profit rose to $37.0 million from $14.6 million, and EBITDA rose 80.8% to $50.7 million. Trasteel reaffirmed its full-year 2026 projections, and the business combination with Sizzle II is expected to close by the end of 2026, subject to Sizzle II shareholder approval.
Total revenue of $1,192.4 million in H1 2026, up 40.0% from $851.8 million in H1 2025
EBITDA of $50.7 million, up 80.8% from $28.0 million; operating profit of $37.0 million versus $14.6 million
Gross profit of $105.9 million, up 36.9%, while gross profit as a percentage of total revenue slipped to 8.9% from 9.1%
FY 2026 projections: revenue $2.1-2.5 billion, gross profit $200 million, EBITDA $80-85 million; results are unaudited and not PCAOB reviewed
Bumble Inc. agreed on October 12, 2026 to be acquired by Ithaca Holdings in an all-cash deal valuing the company at $1.3 billion, with Class A shareholders receiving $6.05 per share, a premium of about 138% to the unaffected October 9, 2026 closing price. Stockholder written consent has already been delivered by the Principal Stockholders, so no further shareholder vote is required, and the company will not issue a third-quarter 2026 earnings release.
Class A common stock holders to receive $6.05 per share in cash, about 138% premium to the unaffected closing price on October 9, 2026
Company termination fee of $29 million may apply under certain circumstances; Ithaca Holdings would pay a $102 million parent termination fee in specified cases, to be deposited in escrow by October 19, 2026
Merger must close by July 12, 2027 or either party may terminate; the company will file its Form 10-Q for the third quarter by November 9, 2026 and will not hold an earnings call
Mirum Pharmaceuticals announced topline results from the Phase 3 EXPAND study of Livmarli (maralixibat) in ultra-rare cholestatic liver diseases, saying the study met its primary endpoint. In the pediatric primary analysis, pruritus improved 1.81 points from baseline on maralixibat versus 0.83 points on placebo, and the company plans to submit a U.S. supplemental New Drug Application in the first half of 2027.
Primary endpoint: 1.81-point improvement on maralixibat vs. 0.83 on placebo, a placebo-adjusted difference of 0.98 points (p=0.0004)
Serum bile acids fell 70.1% on maralixibat vs. 3.5% on placebo, a 69.0% treatment effect (p<0.0001)
No new safety signals; diarrhea reported in 64.0% of maralixibat patients vs. 11.1% on placebo
Supplemental New Drug Application planned in the United States in the first half of 2027
Goldman Sachs reported third-quarter 2026 net revenues of $18.68 billion, up 23% from the third quarter of 2025 but down 8% from the second quarter of 2026. Diluted earnings per share were $17.01, compared with $12.25 a year earlier and $20.98 in the prior quarter, so shareholders see higher year-over-year profit but a sequential decline.
Net revenues $18.68 billion, up 23% year over year and down 8% from the second quarter of 2026
Diluted EPS $17.01 versus $12.25 in Q3 2025 and $20.98 in Q2 2026; net earnings $5.29 billion
Annualized return on average common shareholders' equity 18.7%; book value per share $372.64
Board declared a $5.00 per share dividend payable December 30, 2026, to holders of record on December 2, 2026
JPMorgan Chase reported third-quarter 2026 net income of $15.3 billion, or $5.57 per diluted share, up 6% in net income and 10% in EPS from the third quarter of 2025. Reported net revenue rose 8% to $50.2 billion, while $658 million of net investment securities losses reduced EPS by $0.18; excluding that item, net income was $15.8 billion. The Firm also declared a $1.65 per share common dividend and said it reduced share repurchases this quarter.
Net income $15.3 billion, up 6% year over year; diluted EPS $5.57 versus $5.07
Reported net revenue $50.2 billion, up 8%; noninterest expense $27.3 billion, up 12%
$658 million of net investment securities losses reduced EPS by $0.18; excluding the item, net income was $15.8 billion and EPS $5.75
Common dividend of $1.65 per share; $664 million of net common stock repurchases in the quarter
Reliance Global Group said it repaid in full its Oak Street Funding term loan, its only term debt, leaving no outstanding term debt. The loan had a balance of about $4.4 million as of June 30, 2026, and the repayment was funded by proceeds from two agency sales and collateral cash, without issuing shares. The company reports more than $6 million of cash after the repayment and says it eliminates about $1 million of annual principal, interest and fee payments.
Oak Street Funding term loan repaid in full; balance was about $4.4 million as of June 30, 2026.
Funding: about $1.2 million from the Southwestern Montana Insurance Center sale (closed September 11, 2026), about $2.2 million from the Altruis Benefit Consulting sale (closed September 24, 2026), and about $1.0 million of collateral cash.
Eliminates about $1 million of annual principal, interest and fee payments; company reports more than $6 million of cash on its balance sheet afterward.
Wells Fargo reported third quarter 2026 net income of $5,951 million, or $1.87 per diluted share, compared with $5,589 million and $1.66 a year earlier. Revenue rose 2% from a year ago to $21,870 million, but fell 3% from the second quarter, when EPS was $2.00, and the provision for credit losses rose 51% from a year ago.
Diluted EPS of $1.87 rose 13% from $1.66 a year ago but fell 6% from $2.00 in the second quarter of 2026.
Total revenue was $21,870 million, up 2% from a year ago; noninterest expense fell 1% to $13,743 million.
Provision for credit losses rose to $1,029 million from $681 million a year ago; CET1 ratio was 10.0%, down from 11.0%.
The company repurchased 28.6 million shares, or $2.5 billion, of common stock in the third quarter.
Nurix Therapeutics reported results for the fiscal quarter ended August 31, 2026. Total revenue rose to $673.1 million from $7.9 million a year earlier, mainly from $653.2 million of license revenue tied to the Roche collaboration, and the company reported net income of $549.8 million, or $4.73 per diluted share, compared with a net loss of $86.4 million a year earlier. Because most of the revenue came from a single license payment, the filing's profit figures are driven by that item rather than by recurring sales.
Total revenue was $673.1 million, versus $7.9 million a year earlier, including $653.2 million of Roche license revenue.
Net income was $549.8 million, or $4.73 per diluted share, versus a net loss of $86.4 million, or $1.03 per share, a year earlier.
General and administrative expenses rose to $34.4 million from $13.2 million, mainly due to one-time Roche transaction costs.
Cash, cash equivalents and marketable securities were $1.1 billion as of August 31, 2026, versus $592.9 million on November 30, 2025.
FB Financial Corporation reported third-quarter 2026 net income of $60.2 million, or $1.20 per diluted share, up from $1.13 in the second quarter and $0.43 a year earlier. Total revenue was $174.5 million, roughly flat from the prior quarter, while noninterest expense rose to $96.0 million and the net interest margin fell to 3.83%.
Q3 2026 diluted EPS was $1.20 versus $1.13 in Q2 2026 and $0.43 in Q3 2025; adjusted diluted EPS was $1.21.
Total revenue was $174.5 million, compared with $174.8 million in Q2 2026 and $173.9 million in Q3 2025.
Noninterest expense rose to $96.0 million from $91.5 million in Q2 2026; the net interest margin fell to 3.83% from 3.95%.
Loans held for investment reached $13.18 billion and total deposits $14.67 billion at September 30, 2026; the company repurchased $29.3 million of common stock during the quarter.
UnitedHealth Group reported third quarter 2026 diluted earnings of $4.56 per share, up from $2.59 a year earlier, on revenues of $112.7 billion, down slightly from $113.2 billion. The company raised its full-year 2026 outlook to at least $20.50 per share in adjusted earnings, which matters to shareholders because profit rose while the outlook improved.
Diluted EPS was $4.56 versus $2.59 in Q3 2025; adjusted EPS was $4.69 versus $2.92.
Earnings from operations were $6.6 billion versus $4.3 billion; revenues were $112.7 billion versus $113.2 billion.
Full-year 2026 outlook: at least $19.50 per share in diluted earnings and at least $20.50 per share in adjusted earnings.
Medical care ratio was 88.4% versus 89.9% a year earlier; debt-to-capital ratio was 41.7% as of September 30, 2026.
Unity Bancorp reported third-quarter 2026 net income of $17.4 million, or $1.70 per diluted share, up from $14.5 million, or $1.42 per diluted share, in the second quarter. The company said a purchase of transferable federal investment tax credits lowered its tax expense and added a $2.5 million benefit to earnings, and its effective tax rate fell to 13.1% from 22.4%.
Net interest income rose $2.5 million to $34.3 million, and net interest margin increased 11 basis points to 4.67%.
Noninterest expense rose to $15.6 million from $13.9 million, including a one-time $769 thousand supplemental retirement plan expense.
Nine-month net income was $46.1 million, or $4.52 per diluted share, compared with $42.5 million, or $4.15 per diluted share, a year earlier.
SSR Mining filed an updated Technical Report Summary for its Marigold Complex in Nevada, with an effective date of May 1, 2026, and a signature date of October 9, 2026. The report puts total Marigold mineral reserves at 3.96 million ounces of gold, which the filing says is a 73% increase in contained gold over previous estimates, driven by a $2,200 per ounce gold price assumption. The report also notes that Buffalo Valley mining operations are currently unpermitted and depend on permits being secured before planned production begins in 2029.
Marigold Probable Reserves of 240.44 million tonnes grading 0.46 g/t Au, containing 3.52 million ounces; total reserves including stockpiles and leach pad inventory are 3.96 million ounces
The filing says the updated $2,200 per ounce gold price assumption triggered a 73% increase in contained gold versus previous estimates
Buffalo Valley contributes 45.33 million tonnes of Probable Reserves containing 0.67 million ounces, but mining there is currently unpermitted and production is scheduled to begin in 2029
Domino's Pizza reported third-quarter 2026 results for the period ended September 6, 2026, with revenue of $1,185.6 million, up 3.4%, and net income of $152.2 million, up 9.2%. Diluted earnings per share rose 12.7% to $4.60, helped by a lower share count from buybacks, and the board declared a $1.99 per share quarterly dividend. U.S. same store sales grew 0.3%, while free cash flow for the first three fiscal quarters fell 7.2% to $459.8 million.
Total revenues of $1,185.6 million, up 3.4% from $1,147.1 million a year earlier
Net income of $152.2 million, up 9.2%; diluted EPS of $4.60 versus $4.08
U.S. same store sales up 0.3%; international same store sales up 0.2% excluding foreign currency
Quarterly dividend of $1.99 per share, record date December 15, 2026, payable December 30, 2026
ImmuCell Corporation reported preliminary, unaudited third-quarter 2026 total sales of $8.0 million, a 46.0% increase from the third quarter of 2025, and nine-month sales of $25.6 million, up 27.8%. The company said the comparison was aided in part by depressed third-quarter 2025 sales caused by high distributor purchases in the second quarter of 2025. Full financial results are due on a conference call on November 13, 2026, and the company will stop issuing early sales reports.
Q3 2026 total sales were $8.0 million, up 46.0%; domestic sales were $6.9 million, up 29.2%
Nine-month 2026 total sales were $25.6 million, up 27.8% from the nine months ended September 30, 2025
Q3 2025 comparison was depressed by high distributor purchases in Q2 2025
Full results will be discussed on a conference call on Friday, November 13, 2026, at 9:00 AM ET
BridgeBio announced the FDA accepted its New Drug Application for oral infigratinib for children with achondroplasia with Priority Review, setting a PDUFA target action date of February 4, 2027. The company says the drug met its Phase 3 PROPEL 3 primary endpoint, but the filing does not describe financial results or a financial effect, so the update is mainly a regulatory milestone for shareholders.
FDA accepted the NDA with Priority Review; PDUFA target action date is February 4, 2027
PROPEL 3 met its primary endpoint: LS mean treatment difference of +1.74 cm/year and mean treatment difference of +2.10 cm/year in annualized height velocity (p<0.0001)
Oral infigratinib has Breakthrough Therapy Designation; BridgeBio plans to submit a Marketing Authorization Application to the EMA in Q4 2026
Approval is not assured; the filing notes the FDA may not approve the drug on the anticipated timeline or at all
Zenas BioPharma announced on October 12, 2026 new data from its Phase 3 INDIGO trial of obexelimab in IgG4-related disease, presented at the 6th International Symposium on IgG4-Related Disease. The filing includes open-label extension flare and safety results, a glucocorticoid toxicity analysis, and initial vaccine response findings, which the company says add to the clinical evidence for obexelimab.
Estimated 12-month probability of remaining flare-free was 0.93 (adjudicated flares) and 0.87 (investigator-determined flares), with five patients pending adjudication.
Obexelimab significantly reduced cumulative glucocorticoid toxicity versus placebo at week 52 (GTI Cumulative Worsening Score difference -11.4; p=0.021).
In a vaccine sub-study, 6 of 7 (86%) participants reached influenza seroimmunity and 4 of 4 (100%) reached COVID-19 seroimmunity during a treatment-free window.
Phase 2 SunStone trial of obexelimab in systemic lupus erythematosus has topline results expected in 4Q 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.